FHI Clinical, a subsidiary of FHI 360, has partnered with Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit organization, to provide full-service contract research organization (CRO) capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19. FHI 360’s data management and biostatistics teams are providing support to FHI Clinical. This clinical trial is investigating a cell therapy developed by Celularity, a clinical-stage cell therapeutics company, as a potential treatment option against the novel coronavirus. To learn more, read the full press release.
